Verona Pharma PLC (LSE:VRP) - Overview

Stock Report

Verona Pharma PLC VRP

Last Price
GBX3.29

Day Change
-0.04|-1.20%

As of 06/12/2016
08:08:24 GMT | GBX
Minimum 15 Minutes Delay.

Last Close3.33p
Day Range3.25 - 3.29
Mkt Cap85.19Mil
52-Wk Range2.17 - 5.25
Yield %0.00
ISINGB00B06GSH43
Volume204,500
P/E-4.52
P/SInfinity
P/CF-5.26

Share Price

Total Returns 05/12/2016

 Chg (%)  
More ...
Verona Pharma PLC-14.74 
FTSE 100 TR GBP1.22
 
Financials
201320142015
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-2.82-3.79-8.97
Net Profit-2.53-2.76-7.42
Reported EPS-0.74-0.32-0.73
Balance Sheet
Current Assets0.8511.265.57
Non Current Assets1.701.871.83
Total Assets2.5613.137.40
Current Liabilities0.490.531.81
Total Liabilities0.490.531.81
Total Equity2.0712.615.59
Cash Flow
Operating Cash Flow-2.34-3.83-7.05
Net Change in Cash-0.369.37-6.44
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2016-10.30-0.46--7.16---
2017-22.67-0.72--4.60---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
09/08/2016PurchaseDr. Jan-Anders Karlsson3.25600,00019,494.00
20/01/2016PurchaseDr. David Ebsworth2.50400,00010,000.00

Company Profile

Verona Pharma PLC is a biopharmaceutical company developing drugs for patients with chronic, debilitating respiratory diseases that are not well treated by existing medicines.
 

Sector

Biotechnology

Market Position

923 of 1864 Companies

Index

FTSE AIM All Share

Outlook

(13/09/2016) no outlook statement

Next Event 31/12/2016

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-4.7213.5916.10
Div Yld (E)0.004.234.35
PEG (E)0.000.550.19
ROCE-235.52209.79-30.25
Op Mrgn0.00-15.64-33.57
EPS Grwth0.008.6822.86
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. David Ebsworth
Chief Executive OfficerDr. Jan-Anders Karlsson
Chief Financial OfficerPiers Morgan
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.